[ad_1]
GlobeNewswire
Allakos announces the price of the public offering of ordinary shares
REDWOOD CITY, Calif., October 28, 2020 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotech company that develops AK002 for the treatment of eosinophils and mast cell-related diseases, today announced the price of its previously announced signed public offer. The size of the offering is $ 250 million worth of its common stock. The Company is offering 3,048,781 shares at a public offering price of $ 82.00 per share. The offer is expected to end on November 2, 2020, subject to the fulfillment of customary closing conditions. In connection with the offer, the Company has granted subscribers a 30-day option to purchase up to 457,317 additional common shares at the public offering price, less discounts and subscription fees. Offer Summary Jefferies, BofA Securities and SVB Leerink are acting as joint accounting managers for the offering. LifeSci Capital LLC and William Blair are acting as co-managers for the offering. The Company currently plans to use the net proceeds of the offering to general business purposes. An effective registration statement relating to the securities sold in this offering was filed with the Securities and Exchange Commission (“SEC”) on 5 August 2019. Copies of the registration statement, the supplement to the preliminary prospectus and the attached prospectus relating to the offering have been filed with the SEC and a supplement to the final prospectus and the accompanying prospectus will be filed with the SEC and will be accessible through the SEC’s website at www.sec.gov. The offer was made only by way of a supplement to the prospectus and the attached prospectus. If available, copies of the Supplement to the Final Prospectus and the attached prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-547 -6340, or by e-mail to [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at [email protected]; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525, ext. 6132, or by email at [email protected]. This press release will not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction where such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of such states or jurisdictions. Forward-Looking Statements This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. This forward – forward-looking statements include, but are not limited to, the ability and timing for closing the public offering and the intended use of the proceeds from the public offer. Such statements are subject to a number of material factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties relating to market conditions and the satisfaction of customary closing conditions relating to the offer, and other risks and uncertainties relating to the offer, the Company and its activities as set out in the Company’s registration statement on Form S-3 filed with the SEC on 5 August 2019 and the prospectus and the supplement to the prospectus included or incorporated by reference therein, as well as other documents the Company files from time to time with the SEC, including Allakos’ most recent annual report on Form 10-K filed with the SEC on February 25 2020 and the quarterly report on Form 10-Q filed with the SEC on August 10, 2020 n identify and identify important factors that could cause Allakos ‘actual results to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release are effective only as of the date of this document and Allakos expressly disclaims any obligation to update any forward-looking statements, except as required by law. Source: Allakos Inc. CONTACT: Investor Contact: Adam Tomasi, President and COO [email protected] Media Contact: Denise Powell [email protected]
Source link
